cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE 00:00:00 11/11/2026 +03			5-day change	1st Jan Change
0.3837 ^USD	+0.71%		-8.42%	-71.58%

11-02	CbdMD, Inc. completed the acquisition of Operating assets and brands of Twinlab Consolidation Corporation.	CI
09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI

Last Transcript: cbdMD, Inc.

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

08-14

More transcripts

Analysts' recommendations: cbdMD, Inc.

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	01/03/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	01/01/2019
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	01/03/2017
William Raines BRD	Director/Board Member	66	19/04/2019
Scott Stephen CHM	Chairman	60	03/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
10/11/26	$0.3837	+0.71%	53,488
09/11/26	$0.3810	-8.41%	235,893
06/11/26	$0.4160	+7.22%	54,981
05/11/26	$0.3880	-4.43%	65,075
04/11/26	$0.4060	-3.10%	170,369

Delayed Quote NYSE

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.3837

Average target price

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - cbdMD, Inc.

Revisions to estimates

Quarterly earnings, Rate of surprise

Rate of surprise - EPS - Quarterly - cbdMD, Inc.

Company calendar

Market Cap	4.3M 3.86M 3.55M 3.23M 6.11M 403M 6.28M 42.55M 16.95M 216M 16.14M 15.79M 683M	P/E 2026 *	-1.16x	P/E 2027 *	-2.02x
Enterprise Value	4.3M 3.86M 3.55M 3.23M 6.11M 403M 6.28M 42.55M 16.95M 216M 16.14M 15.79M 683M	EV / Sales 2026 *	0.2x	EV / Sales 2027 *	0.15x
Free-Float	70.1%	Yield 2026 *	-	Yield 2027 *	-

11-02	CbdMD, Inc. completed the acquisition of Operating assets and brands of Twinlab Consolidation Corporation.	CI
09-02	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI
08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
08-14	CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026
08-13	CbdMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
07-15	CbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina	CI
07-14	CbdMD Expands Oasis Beverage Distribution to South Carolina	MT
07-07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
06-16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
05-15	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-15	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI

09-24	Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation	PR
09-02	CbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness	PR
08-13	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
08-10	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
08-03	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR

1 day	+0.71%
1 week	-8.42%
Current month	+0.26%
1 month	-1.59%
3 months	-32.21%
6 months	-54.32%
Current year	-71.58%

1 week	0.38	0.42
1 month	0.33	0.46
Current year	0.33	1.34
1 year	0.33	2.56
3 years	0.33	13.84
5 years	0.33	727.2
10 years	0.33	2,606.4

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news: cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly earnings, Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/14/26 A	Jeffrey Porter	Free	Director	1,572	0.0150%
4/14/26 A	William Raines	Free	Director	1,572	0.0150%
4/14/26 A	Bakari Sellers	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+0.71%	-8.42%	-52.28%	-93.24%	4.3M
ELI LILLY AND COMPANY	+1.44%	+1.63%	+48.17%	+139.63%	1,276B
JOHNSON & JOHNSON	-0.47%	+5.49%	+49.03%	+90.68%	676B
ABBVIE INC.	+0.20%	+2.76%	+34.37%	+112.06%	519B
ROCHE HOLDING AG	-0.71%	+0.91%	+38.38%	+67.33%	388B
MERCK & CO., INC.	-0.48%	+2.34%	+70.66%	+46.02%	365B
NOVARTIS AG	-1.08%	-0.76%	+28.02%	+57.46%	307B
ASTRAZENECA PLC	-0.20%	-1.03%	+3.07%	+35.44%	287B
AMGEN INC.	0.00%	+0.86%	+43.74%	+74.04%	252B
GILEAD SCIENCES, INC.	+0.92%	+2.03%	+44.62%	+125.07%	212B
Average	-0.32%	+1.26%	+30.78%	+65.45%	428B
Weighted average by Cap.	-0.62%	+2.51%	+42.76%	+96.57%

	2026 *	2027 *
Net sales	21.92M 19.66M 18.12M 16.46M 31.14M 2.06B 32.01M 217M 86.44M 1.1B 82.27M 80.53M 3.48B	28.6M 25.64M 23.63M 21.46M 40.62M 2.68B 41.75M 283M 113M 1.44B 107M 105M 4.54B
Net income	-3.33M -2.99M -2.75M -2.5M -4.73M -312M -4.87M -32.97M -13.14M -167M -12.5M -12.24M -529M	-4.95M -4.44M -4.09M -3.71M -7.03M -464M -7.22M -48.95M -19.5M -248M -18.56M -18.17M -785M
Net Debt	-	-

Markets		Quality
NYSE	YCBD	Delayed
CBOE	YCBD	Real-time